Table 1 Recent patent applications related to histone lysine demethylases
Publication numbers | Applicants | Subject |
|---|---|---|
WO 2013033688 | Brigham And Women's Hospital | Inhibitors of LSD1 and/or LSD2 — including statins — and methods of using them to treat cancer |
WO 2012150042 EP 2592154 | Cellzome; GlaxoSmithKline | Methods for the identification of molecules that interact with histone demethylase and for the purification of histone demethylase proteins |
WO 2013143597 | GlaxoSmithKline | Demethylase enzyme inhibitors that are useful for changing the epigenetic status of cells |
WO 2012052390 | GlaxoSmithKline | N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of the histone demethylase JMJD3 |
US 2012202875 | GlaxoSmithKline | Methods for treating autoimmune and inflammatory conditions by modifying histone demethylation |
CA 2831143 | GlaxoSmithKline | The use of cyclopropylamine derivatives for inhibiting the activity of LSD1; useful for treating cancer |
US 2013210888 | Harvard College | Histone demethylation mediated by the nuclear amine oxidase homologue LSD1 and a method of monitoring eukaryotic histone demethylase activity based on this |
WO 2012047852 | J. David Gladstone Institute | Methods of modulating HIV transcription involving modulation of enzymatic activity, levels of LSD1 polypeptide and/or LSD1-mediated demethylation of methylated HIV Tat polypeptide |
WO 2012034116 | Johns Hopkins University | Small-molecule inhibitors that act as epigenetic modulators of LSD1 and methods of using them to treat cancer |
US 2012322877 | Johns Hopkins University | Novel bisurea and bisthiourea compounds that are inhibitors of LSD1; useful for treating disorders such as cancer |
US 2013197088 | Johns Hopkins University; Progen Pharma | Combinations of a histone demethylase inhibitor and an ornithine decarboxylase inhibitor that are able to re-express certain silenced genes; useful for treating cancer |
US 2012108648 | Kumamoto University | LSD1 inhibitors as novel agents that improve mitochondrial function, and an agent that induces PGC1α expression; useful for treating cranial nerve disease, myopathy and heart disease |
WO 2012071469 | Nevada Cancer Institute et al. | Histone demethylase inhibitors that can be used to treat cancer |
US 2013095067 | Oryzon Genomics | Lysine demethylase inhibitors that are useful for treating disorders associated with Hepadnaviridae infection; they modulate the ability of viruses to use the host cell machinery and reduce replication |
WO 2012156537 | Oryzon Genomics | An LSD1 inhibitor that can be used to treat thrombosis, thrombus formation or cardiovascular disease |
WO 2012156531 | Oryzon Genomics | An LSD1 inhibitor that can be used to treat inflammation and inflammatory diseases |
WO 2012107499 | Oryzon Genomics | An LSD1 inhibitor that can be used for treating myeloproliferative and lymphoproliferative disorders |
WO 2012107498 | Oryzon Genomics | An LSD1 inhibitor; useful for treating Philadelphia chromosome-negative myeloproliferative disorders |
WO 2012072713 | Oryzon Genomics | An LSD1 inhibitor that can be used for treating Flaviviridae infections, including hepatitis C virus infection |
WO 2013022047 | Takeda | A cyclopropane-amine compound that inhibits LSD1; useful for treating cancer and CNS diseases |
US 2013137720 | University of Colorado | A methyl-lysine mimic and an α-ketoglutarate mimic that are attached through a linker; the compound acts as a histone demethylase inhibitor |
US 2012142784 | University of Freiburg et al. | LSD1 as a novel biomarker for breast cancer, and its use for the diagnosis of breast cancer; a method of determining the amount of LSD1 protein and the effect of LSD1 inhibitors on cancer cells |
CN 102985402 | University of Rome et al. | Tranylcypromine derivatives as inhibitors of LSD1 and/or LSD2; useful for treating tumours and viral infections |
WO 2013025805 | University of Utah | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogues that inhibit LSD1 |
US 2013123344 | National Institutes of Health | A method of preventing or treating viral infection using compounds that inhibit JMJD2 proteins |
CN 103054869 | Zhengzhou University | An amino dithio formic ester compound with triazolyl that inhibits LSD1 and can be used as a lead compound for a novel antitumour agent |
